Trials / NCT06891885
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Recruiting now Phase 1 / Phase 2 Gene therapy, Cell therapy
- Sponsor
- Sumitomo Pharma America, Inc.
- Treatment
- DSP-3077 Retinal Sheet Cohort 1; DSP-3077 Retinal Sheet Cohort 2; DSP-3077 Retinal Sheet Cohort 3
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 12 participants
- Started
- 2026-04-16
- Main results expected
- 2028-10-31
- Results posted
- Not yet
- Record last updated
- 2026-04-17
What the study is testing
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.
Where it runs
United States (2)
- Massachusetts Eye and Ear, Boston, Massachusetts (recruiting now)
- University of Minnesota, Minneapolis, Minnesota (recruiting now)